Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after stopping their prescription, ...

Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine.

GLP-1 drugs like Ozempic and Mounjaro helped men with low testosterone raise their levels without hormone replacement in a ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor agonists offer neuroprotective and cerebrovascular benefits beyond what can ...